[go: up one dir, main page]

WO2025038846A1 - Formulations de l-arginine et procédés de gestion de la douleur - Google Patents

Formulations de l-arginine et procédés de gestion de la douleur Download PDF

Info

Publication number
WO2025038846A1
WO2025038846A1 PCT/US2024/042493 US2024042493W WO2025038846A1 WO 2025038846 A1 WO2025038846 A1 WO 2025038846A1 US 2024042493 W US2024042493 W US 2024042493W WO 2025038846 A1 WO2025038846 A1 WO 2025038846A1
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
certain embodiments
pain
acid
biopterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/042493
Other languages
English (en)
Inventor
Claudia R. Morris
Lou Ann Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2025038846A1 publication Critical patent/WO2025038846A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids

Definitions

  • SCD Sickle cell disease
  • acetaminophen may contribute to “asthma-like” symptoms.
  • acute vaso-occlusive painful episodes associated with sickle cell disease (SCD) are frequently treated with morphine.
  • SCD often fail to achieve adequate analgesia with standard doses of morphine.
  • Rondon et al. report L-arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats. Eur J Nutr, 2018, 57:2353-2363. Onalo et al. report randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol, 2021, 96(l):89-97.
  • tyrosine-arginine is an opioid analgesic dipeptide that has established the physiological significance as a neuromodulating peptide.
  • compositions and methods for managing pain generally using L- arginine relate to pharmaceutical formulations comprising L-arginine and a biopterin such as tetrahydrobiopterin.
  • the pharmaceutical composition further comprises acetaminophen and/or N-acetylcysteine.
  • the L-arginine formulation is an aqueous liquid suitable for intravenous injection which increases endogenous formation of kyotorphin.
  • the L-arginine formulation is an aqueous liquid sufficient for intravenous or oral consumption. In certain embodiments, the L-arginine formulation is in a solid form sufficient for oral consumption.
  • the L-arginine formulation further comprises a non-steroidal antiinflammatory drug.
  • the non-steroidal anti-inflammatory drug is ibuprofen or ketorolac.
  • the pharmaceutical composition further comprises kyotorphin.
  • the pharmaceutical composition further comprises morphine.
  • the pharmaceutical composition further comprises glutathione or liposomal glutathione.
  • this disclosure relates to methods of treating or preventing pain comprising administering an effective amount of L-arginine in a pharmaceutical formulation as reported herein to a human patient in need thereof.
  • the formulation comprises L-arginine and tetrahydrobiopterin.
  • this disclosure relates to methods of treating or preventing pain, acute or chronic pain, neuropathic pain, traumatic pain, comprising administering an effective amount of L-arginine and a biopterin to a human patient in need thereof wherein the patient is diagnosed with acute or chronic pain, neuropathic pain, traumatic pain, or pain associated with sickle cell disease (SCD).
  • SCD sickle cell disease
  • the patient is diagnosed with sickle cell disease (SCD).
  • SCD sickle cell disease
  • the patient is diagnosed with homozygous sickle hemoglobin [Hb-SS], thalassemia, hemoglobin S (sickle hemoglobin), or hemoglobin sickle beta zero thalassemia [Hb-SpO- thalassemia].
  • Hb-SS homozygous sickle hemoglobin
  • thalassemia thalassemia
  • hemoglobin S thinle hemoglobin
  • Hb-SpO- thalassemia hemoglobin sickle beta zero thalassemia
  • the subject is less than 16 or 21 years old.
  • the patient is diagnosed with acute pain.
  • the patient is diagnosed with chronic pain.
  • this disclosure relates to methods of treating or preventing traumatic pain, fractures/orthopedic pain, surgical pain/post-op pain. In certain embodiments, this disclosure relates to methods of treating or preventing pain comprising administering an effective amount of a pharmaceutical composition comprising L-arginine as reported herein to a subject in need thereof prior to surgery or during surgery or after surgery.
  • Figure 1A shows data on the impact of intravenous arginine therapy on arginine concentration (pM) after arginine supplementation at different time points. Plasma concentration remains significantly above baseline through 8 hours for arginine.
  • Figure IB shows data on the impact of intravenous arginine therapy on kyotorphin concentrations (pM) after arginine supplementation at different time points. Plasma concentrations remains significantly above baseline through 2 hours for KTP (kyotorphin).
  • Figure 2A shows data indicating arginine and kyotorphin levels are closely correlated in SCD patients after arginine therapy.
  • Figure 2B shows data indicating arginine levels are elevated in the treatment group at time of discharge suggesting therapy increases kyotorphin levels, improves mitochondrial function, and decreases pain compared to standard of care medications in patients with sickle cell disease.
  • Figure 3 shows data on the time-to-crises resolution and total IV opioids in SCD patients after IV arginine therapy.
  • an “embodiment” of this disclosure refers to an example, and this disclosure is not necessarily limited to such example.
  • Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
  • the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) have the meaning ascribed to them in U.S. Patent law in that they are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
  • compositions like those disclosed herein that exclude certain prior art elements to provide an inventive feature of a claim, but which may contain additional composition components or method steps that do not materially affect the basic and novel characteristics of the compositions or methods.
  • the term "subject” refers to any animal, preferably a human patient, livestock, or domestic pet.
  • the subject is a human subject of any age or a patient 2, 12, 16, or 20 years old or older.
  • the subject is a human subject 55 or 65 years old or older.
  • the subject is a human subject greater than 65, or 70 years of age.
  • the terms “treat” and “treating” are not limited to the case where the subject (e.g., patient) is cured and the disease is eradicated. Rather, embodiments of the present disclosure also contemplate treatment that merely reduces symptoms, and/or delays disease progression. As used herein, the terms “prevent” and “preventing” include the prevention of the recurrence, spread or onset. It is not intended that the present disclosure be limited to complete prevention. In some embodiments, the onset is delayed, or the severity is reduced.
  • an effective amount refers to that amount of a compound or pharmaceutical composition described herein that is sufficient to effect the intended application including, but not limited to, disease treatment.
  • the therapeutically effective amount can vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • the specific dose will vary depending on, for example, the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
  • the term "combination with” when used to describe administration with an additional treatment means that the agent may be administered prior to, together with, or after the additional treatment, or a combination thereof.
  • an “anti-inflammatory agent” refers to a compound generally recognized to be administered to reduce symptoms of inflammatory process such as discolored tissue, tissue swelling, heat, or fever. Suitable anti-inflammatory agents both steroidal and non-steroidal structures such as aspirin and acetaminophen. Additional examples of “nonsteroidal antiinflammatory drugs” or “NSAIDs” include ibuprofen, ketorolac, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, and indomethacin.
  • steroidal anti-inflammatory agents include corticosteroids such as hydrocortisone, cortisol, triamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoximetasone, desoxycorticosterone acetate, dexamethasone, diflorasone diacetate, diflucortolone valerate, fluadr enol one, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluocinolone acetonide, fluocinonide, fluocortin butyl ester, fluocortolone, fluprednidene acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone, hydro
  • this disclosure relates to pharmaceutical formulations comprising L-arginine and a biopterin such as tetrahydrobiopterin.
  • the pharmaceutical composition further comprises acetaminophen and/or N-acetylcysteine.
  • the L-arginine formulation is an aqueous liquid suitable for intravenous injection which increases endogenous formation of kyotorphin.
  • the L-arginine formulation further comprise kyotorphin.
  • the L-arginine formulation is an aqueous liquid suitable for intravenous injection which increases endogenous formation of kyotorphin.
  • the L-arginine formulation is an aqueous liquid sufficient for intravenous or oral consumption.
  • the formulation is an isotonic aqueous liquid optionally comprising a saccharide or polysaccharide or optionally comprising salts, e.g., such that the electrolyte content is similar to a solution of 0.9% NaCl or 5% glucose, i.e., solution that has the same osmolarity as blood plasma or approximately 310 mEq/L or between 300 and 320 mEq/L or between 290 and 330 mEq/L.
  • the L-arginine formulation is in a solid form sufficient for oral consumption.
  • the L-arginine formulation further comprises an antiinflammatory agent such as a non-steroidal anti-inflammatory drug.
  • an antiinflammatory agent such as a non-steroidal anti-inflammatory drug.
  • the non-steroidal anti-inflammatory drug is acetaminophen.
  • the non-steroidal anti-inflammatory drug is ibuprofen or ketorolac.
  • the pharmaceutical composition further comprises kyotorphin.
  • the pharmaceutical composition further comprises morphine.
  • the pharmaceutical composition comprises elevated amounts of L-arginine, e.g., 200 mg or more per unit dose.
  • the pharmaceutical formulation comprises: i) L-arginine, e.g., at 250 mg to 20 grams per unit dose; ii) biopterin e.g., tetrahydrobiopterin, e.g., 10 to 1500 mg per unit dose iii) acetaminophen, e.g., at 50 mg to 650 mg per unit dose; and iv) N-acetyl cysteine, e.g., at 100 mg to 15 grams per unit dose.
  • L-arginine e.g., at 250 mg to 20 grams per unit dose
  • biopterin e.g., tetrahydrobiopterin
  • acetaminophen e.g., at 50 mg to 650 mg per unit dose
  • N-acetyl cysteine e.g., at 100 mg to 15 grams per unit dose.
  • the formulation further comprises glutathione.
  • the pharmaceutical formulation comprises: i) L-arginine, e.g., at 250 mg to 20 grams per unit dose; ii) biopterin e.g., tetrahydrobiopterin, e.g., at 10 to 1500 mg per unit dose, and iii) ibuprofen.
  • the pharmaceutical formulation comprises: i) L-arginine, e.g., at 250 mg to 20 grams per unit dose; ii) biopterin, e g., tetrahydrobiopterin, e.g., 10 to 1500 mg per unit dose iii) acetaminophen, e.g., at 50 mg to 650 mg per unit dose; iv) N-acetyl cysteine, e.g., at 100 mg to 15 grams per unit dose; and v) ibuprofen or ketorolac or other nonsteroidal anti-inflammatory drug (NSAID).
  • L-arginine e.g., at 250 mg to 20 grams per unit dose
  • biopterin e.g., tetrahydrobiopterin
  • acetaminophen e.g., at 50 mg to 650 mg per unit dose
  • N-acetyl cysteine e.g., at 100 mg to 15 grams per unit dose
  • NSAID nonsteroidal
  • the formulation further comprises glutathione.
  • the pharmaceutical formulation comprises: i) L-arginine, e.g., at 250 mg to 20 grams per unit dose; ii) biopterin, e.g., tetrahydrobiopterin, e.g., 10 to 1500 mg per unit dose iii) acetaminophen, e.g., at 50 mg to 650 mg per unit dose; iv) N-acetyl cysteine, e.g., at 100 mg to 15 grams per unit dose; and v) L-citrulline e.g., 50 mg- 10 grams per unit dose.
  • L-arginine e.g., at 250 mg to 20 grams per unit dose
  • biopterin e.g., tetrahydrobiopterin
  • acetaminophen e.g., at 50 mg to 650 mg per unit dose
  • N-acetyl cysteine e.g., at 100 mg to 15 grams per unit dose
  • L-citrulline e.
  • the formulation further comprises glutathione.
  • the formulation comprises 7 grams of L-arginine per unit dose, 1000 mg of tetrahydrobiopterin per unit dose, 650 mg of acetaminophen per unit dose, 900 mg or N-acetyl cysteine, and 2 grams L-citrulline per unit dose.
  • the formulation further comprises glutathione.
  • the formulation is used in patients with liver dysfunction that do not tolerate acetaminophen or patients with renal dysfunction or patients that do not tolerate ibuprofen the formulation comprising: i) 250 -20 mg of L-arginine per unit dose, ii) biopterin, e.g., tetrahydrobiopterin, iii) N-acetyl cysteine, iv) L-citrulline, and v) optionally acetaminophen, kyotorphin, ketorolac, or other NSAID.
  • the formulation further optional comprises ingredients selected from tyrosine and/or other amino acids including glutamine, taurine, glutathione (liposomal glutathione), L-carnitine/acetyl carnitine, curcumin/turmeric, S-adenosyl-methionine, a mitochondrial cocktail (B-vitamins, alpha lipoic acid, vitamin E, vitamin C,) vitamin D, vitamins A,B,C,D,E,K (KI and K2)), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), zinc, magnesium, calcium, sulforaphane, 5HTP (5 hy droxytryptophan) .
  • tyrosine and/or other amino acids including glutamine, taurine, glutathione (liposomal glutathione), L-carnitine/acetyl carnitine, curcumin/turmeric,
  • the formulation further optional comprises ingredients selected from vitamins and nutrients to create a nutritional complete medical food or meal replacement such as B-vitamins, methyl-folate, methylcobalamin; thiamine niacinamide, pantothenate, riboflavin, biotin, B6/P-5-P (pyrodoxal-5-phosphate), naltrexone, choline, phosphatidylcholine, medium chain triglycerides, iron, potassium, iodine, inositol, copper, selenium, resveratrol, long chain fatty acids, esters of long chain fatty acids, alpha-lipoid acid, a carnitine, probiotics, an omega-6 fatty acid, an esters of omega-6 fatty acid, gamma-linolenic acid, ethyl gamma-linolenate, an omega-9 fatty acid, esters of omega-9 fatty acid, oleic acid, e
  • the formulation further comprises an omega 3 fatty acid and/or omega 6 fatty acid.
  • the composition further comprises fatty acids.
  • the composition comprises medium chain fatty acids with no or low amounts of long chain fatty acids e.g., less than 5% or 2% or 1% of total fatty acids by weight.
  • the formulation further comprises a vitamin E (e.g., alphatocopherol).
  • a vitamin E e.g., alphatocopherol
  • the formulation further comprises one or more or all of the following: coenzyme Q-10 (ubiquinone), B-vitamins (thiamine, riboflavin, niacin, pyridoxine, cobalamin), alpha lipoic acid, vitamin C (L-ascorbic acid), and vitamin E (alpha-tocopherol).
  • the composition further comprises one or more or all of the following: vitamin KI (phylloquinone), carnitine, and creatine.
  • the formulation further comprises one or more all of the essential amino acids, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.
  • the formulation further comprises zinc.
  • zinc is in amount of greater than 8, 11, 15, or 20 mg. In certain embodiments, zinc is in an about of greater than 15, 20, or 30 mg. In certain embodiments, zinc is in an amount of between 30 - 50 mg.
  • the formulation further comprises S-adenosyl-L-methionine (SAMe).
  • SAMe S-adenosyl-L-methionine
  • the formulation further comprises melatonin.
  • the formulation further comprises glutathione.
  • the formulation further comprises calcium.
  • the formulation further comprises magnesium.
  • the formulation further comprises selenium.
  • the formulation further comprises vitamin A.
  • the formulation further comprises vitamin Bl.
  • the formulation further comprises vitamin B2.
  • the formulation further comprises vitamin B3.
  • the formulation further comprises vitamin B5.
  • the formulation further comprises vitamin B6.
  • the formulation further comprises vitamin B7.
  • the formulation further comprises vitamin B9.
  • the formulation further comprises vitamin B 12
  • the formulation further comprises vitamin C.
  • the formulation further comprises a vitamin D.
  • the formulation further comprises a vitamin K. In certain embodiments, the formulation further comprises glutamine.
  • the formulation further comprises pyridoxal-5-phosphate.
  • the formulation further comprises methylcobalamin.
  • the formulation further comprises L-methylfolate (5-MTHF).
  • the formulation further comprises citrulline.
  • the formulation further comprises citrulline and glycine.
  • the additional components are selected from long or medium chain fatty acids, esters of long chain fatty acids, alpha-lipoic acid, carnitine, an omega-6 fatty acid, esters of omega-6 fatty acid, gamma-linolenic acid, ethyl gamma-linolenate, an omega-9 fatty acid, esters of omega-9 fatty acid, oleic acid, ethyl oleate, zinc, calcium, magnesium, selenium, a vitamin A, a vitamin Bi, a vitamin B2, a vitamin B3, a vitamin B5, a vitamin Be, a vitamin B7, a vitamin B9, a vitamin B12, vitamin C, vitamin D, vitamin K, S-adenosylmethionine, a phosphocholine, creatine, a coenzyme Q, taurine, tetrahydrobiopterin, methylcobalamin, betaine, pancreatic enzymes, folinic acid, pancrelipase,
  • “Fatty acids” refers to a family of carboxylic acids having a saturated or unsaturated hydrocarbon chain of about 4 to about 28 carbons in length and is intended to include carboxylic acid salt forms.
  • Medium chain fatty acids (MCFAs) refer to a family of carboxylic acids having a saturated or unsaturated hydrocarbon chain of from about 6 to 10 carbons in length and is intended to include carboxylic acid salt forms. Examples include capric acid, caprylic acid, and hexanoic acid.
  • MCTs Medium-chain triglycerides
  • Natural sources of MCFAs and MCTs include coconut, palm kernel oil, and bovine milk.
  • Long chain fatty acids are typically between 12 and 28 carbons in length. Unsaturated fatty acids have at least one carbon-carbon double bond in the hydrocarbon chain. Unsaturated fatty acids include monounsaturated fatty acids and polyunsaturated fatty acids (PUFAs). Unsaturated fatty acids are designated by the position of the first double bond from the methyl end of the hydrocarbon chain.
  • Omega-3 fatty acids have a first double bond at the third carbon from the methyl end of the chain; and include, e.g., alpha-linolenic acid (ALA) (octadeca- 9,12,15-trienoic acid), stearidonic acid (octadeca-6,9,12,15-tetraenoic acid), eicosapentaenoic acid (eicosa-5,8,11,14,17-pentaenoic acid; "EPA”), docosapentaenoic acid (docosa-7, 10,13,16,19- pentaenoic acid), eicosatetraenoic acid (eicosa-8,l l,14,17-tetraenoic acid), and docosahexaenoic acid (docosa-4,7,10,13,16,19-hexaenoic acid; "DHA").
  • ALA alpha-linolenic acid
  • Ethyl eicosapentaenoate, icosapent ethyl is an omega-3 polyunsaturated fatty acid (PUFA) ester composition FDA approved for the treatment of hypertriglyceridemia.
  • PUFA polyunsaturated fatty acid
  • Omega-6 fatty acids have a first double bond at the sixth carbon from the methyl end of the chain; and include, e.g., linoleic acid (9,12-octadecadienoic acid), gamma-linolenic acid (6,9,12-octadecatrienoic acid; GLA), eicosadienoic acid (11,14- eicosadienoic acid), dihomo-gamma-linolenic acid (8,11,14-eicosatrienoic acid), arachidonic acid (5,8,11,14-eicosatetraenoic acid), docosadienoic acid (13,16-docosadienoic acid), adrenic acid (7,10,13,16-docosatetraenoic acid), docosapentaenoic acid (4,7,10,13,16-docosapentaenoic acid), and calendic acid (8E,10E,12Z-
  • Omega-9 fatty acids have a first double bond at the ninth carbon from the methyl end of the chain; and include, e.g., oleic acid (cis-9-octadecenoic acid); eicosenoic acid (cis-ll-eicosenoic acid); mead acid (all-cis-5,8, 11 - eicosatrienoic acid); erucic acid (cis-13-docosenoic acid); and nervonic acid (cis-15-tetracosenoic acid).
  • oleic acid cis-9-octadecenoic acid
  • eicosenoic acid cis-ll-eicosenoic acid
  • mead acid all-cis-5,8, 11 - eicosatrienoic acid
  • erucic acid cis-13-docosenoic acid
  • nervonic acid cis-15-tetracosenoic acid
  • formulations may contain an additional pharmaceutically acceptable carrier.
  • the composition can be in dosage unit form such as liquid, gel, tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, particles, or the like.
  • An acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound such as a compound of the disclosure.
  • physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose, dextran, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
  • carrier means a material, composition, or vehicle, such as a liquid or solid fdler, diluent, excipient, solvent, or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the recipient.
  • materials which can serve as acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
  • Formulations of the disclosure suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and the like, each containing a predetermined amount of compounds.
  • Compositions or compounds may also be administered as a bolus, electuary, or paste.
  • the active ingredient(s) are mixed with one or more acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fdlers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as
  • compositions may also comprise buffering agents, e.g., such that the solution is around a pH of 7 or between a pH of 6.5 to 8.0.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using a binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the compositions may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • opacifying agents include polymeric substances and waxes.
  • the active ingredient(s) can also be in micro-encapsulated form, if appropriate, with one or more of the abovedescribed excipients.
  • compositions suitable for parenteral administration may comprise one or more active compounds in combination with one or more sterile isotonic solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation aqueous pH buffered and isotonic with the blood of the intended recipient or suspending or thickening agents.
  • nonaqueous carriers examples include ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like.
  • isotonic agents such as sugars, sodium chloride, and the like into the compositions.
  • prolonged absorption of the injectable form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
  • the effective daily doses of the compounds may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • the compounds may be administered two or three times daily. In preferred embodiments, the compounds will be administered once daily.
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the formulations.
  • this disclosure relates to treating or preventing general pain such as acute or chronic pain, neuropathic pain, traumatic pain, or pain associated with sickle cell disease (SCD) or associated side effects comprising administering an effective amount of arginine, a biopterin such as tetrahydrobiopterin, and to a subject or human patient in need thereof.
  • SCD sickle cell disease
  • methods of treating pain are not limited to sickle cell disease i.e., SCD is one example of a group experiencing pain who would benefit.
  • the biopterin is biopterin, dihydrobiopterin, tetrahydrobiopterin, or combinations thereof.
  • the patient is diagnosed with general acute or chronic pain, neuropathic pain, traumatic pain, or pain associated with sickle cell disease (SCD). In certain embodiments, the patient is diagnosed with acute pain. In certain embodiments, the patient is diagnosed with chronic pain. In certain embodiments, the subject is a human child diagnosed with SCD having vasoocclusive pain episodes (VOE). In certain embodiments, the patient is diagnosed with sickle cell disease (SCD).
  • SCD sickle cell disease
  • the patient is diagnosed with homozygous sickle hemoglobin [Hb-SS] or hemoglobin sickle beta zero thalassemia [Hb-SpO-thalassemia],
  • this disclosure relates to methods of treating or preventing traumatic pain, fractures/orthopedic pain, or surgical pain/post-op pain.
  • this disclosure relates to methods of treating or preventing pain comprising administering an effective amount of a L-arginine and a biopterin and optionally other agents reported herein prior to surgery or during surgery or after surgery.
  • this disclosure relates to treating or preventing pain associated with sickle cell disease comprising administering an effective amount of L-arginine and a biopterin to a human patient in need thereof.
  • L-arginine is administered to the subject intravenously at 200 mg/kg or greater. In certain embodiments, L-arginine is administered intravenously at 300 mg/kg or greater. In certain embodiments, L-arginine is administered intravenously at 400 mg/kg or greater. In certain embodiments, L-arginine is administered intravenously at 500 mg/kg or greater.
  • the biopterin is tetrahydrobiopterin.
  • the formulation further comprises glutathione or/and liposomal glutathione.
  • methods further comprise administering L-arginine and the biopterin in combination with acetaminophen or N-acetylcysteine to the subject.
  • methods further comprise administering L-arginine and the biopterin in combination with morphine to the subject.
  • methods include administration of L-arginine and the biopterin in a single pharmaceutical composition wherein the pharmaceutical composition further optionally comprises acetaminophen and/or N-acetylcysteine.
  • the formulation further comprises glutathione.
  • methods include administration of L-arginine and the biopterin in combination with morphine (co-admini strati on) at lower doses.
  • the subject is administered less than 20 mg of morphine every 12 hours. In certain embodiments, the subject is administered less than 15 mg of morphine every 12 hours. In certain embodiments, the subject is administered less than 10 mg of morphine every 12 hours. In certain embodiments, the subject is administered less than 5 mg of morphine every 12 hours.
  • SCD Sickle cell disease
  • arginine therapy increases kyotorphin levels in the plasma of patients with sickle cell disease experiencing pain.
  • Arginine alone or in combination with other ingredients provides a non-toxic treatment of pain in sickle cell disease that can be applied to other acute and chronic pain syndromes.
  • BH4 tetrahydrobiopterin
  • biopterins supports the arginine pathway that is sometimes dysfunctional in pain syndromes.
  • Additional ingredients contemplated in the analgesic formulations include acetaminophen and N- acetylcysteine (which may protect against the adverse effects of acetaminophen on the liver and other organs), and/or glutathione (liposomal glutathione may be added to provide stability and bioavailability), curcumin, ibuprofen, and/or S-adenosyl-methionine (which supports reduced glutathione production) and optionally exogenous kyotorphin.
  • acetaminophen and N- acetylcysteine which may protect against the adverse effects of acetaminophen on the liver and other organs
  • glutathione liposomal glutathione may be added to provide stability and bioavailability
  • curcumin ibuprofen
  • S-adenosyl-methionine which supports reduced glutathione production
  • optionally exogenous kyotorphin optionally exogen
  • Contemplated mitochondrial cocktails include agents such as B-vitamins, alpha lipoic acid, co- Q10, vitamin E, vitamin C, an omega 3 fatty acid, a vitamin E, other essential amino acids, SAMe, melatonin, and GSH.
  • ingredients in a mitochondrial cocktail include active B- vitamins including methylcobalamin, L-methylfolate (5-MTHF), Bl (thiamine), B2 (riboflavin), niacin, B6 (5-P-5), biotin, pantothenic acid, alpha lipoic acid, Co-QlO, and phosphatidylcholine.
  • Arginine (or kyotorphin) and acetaminophen/N-acetyl cysteine and ibuprofen also represents a contemplated analgesic.
  • NAC N-acetyl cysteine
  • Tylenol® antidote The addition of N-acetyl cysteine (NAC) to acetaminophen/Tylenol® antidote is contemplated to increase the safety of acetaminophen.
  • NAC and glutathione as a pain reliever targets an unmet need and makes acetaminophen safer for patients with SCD who are vulnerable to the effects of low glutathione bioavailability.
  • Low plasma and erythrocyte glutathione levels make sickle-red blood cells more vulnerable to hemolysis.
  • the addition of NAC to an acetaminophen pain reliever creates a safer analgesic.
  • formulations provided herein are in the context of opioid-sparing analgesics for SCD, the formulations and methods disclosed herein may be applied in the treatment of acute and chronic pain generally in the context of other diseases and conditions.
  • VOE vaso-occlusive pain episode
  • SCD sickle cell disease
  • RCT placebo-controlled trials
  • Standard dose 100 mg/kg/dose L-arginine every 8 hours
  • loading dose 200 mg/kg followed by SD or placebo
  • TPO intravenous morphine equivalents, mg/kg
  • secondary outcomes Time-to-cri sisresolution, pain scores, patient-reported outcomes (PROs), arginine bioavailability and biomarkers of oxidative stress/mitochondrial function were evaluated.
  • TPO time-to-crisis-resolution
  • pain scores and PROs at discharge were similar across arms.
  • Plasma arginine was low at presentation in 74% of patients (mean 50 ⁇ 28 pM) and increased significantly in those treated with arginine.
  • Arginine bioavailability at VOE-presentation inversely correlated to time-to-crisis-resolution in the placebo arm only, an association lost after arginine therapy.
  • a dose-dependent increase in platelet- mitochondrial activity was noted after arginine versus no change after placebo; plasma proteincarbonyl levels decreased, suggesting a decrease in oxidative stress with arginine that worsened in the placebo-group.
  • SCD-VOE is associated with an acquired arginine deficiency that correlates with worse clinical outcomes.
  • Intravenous arginine improves mitochondrial function and decreases oxidative stress in patients with SCD-VOE compared to placebo.
  • Significant opioid-sparing is noted in children of ages 5-16 years.
  • Arginine was administered over 30 minutes. Blood was obtained at 6 time points: preinfusion (time 0) and at 1, 1.5, 2, 4, and 8 hours after the initiation of the first arginine infusion, and then at about 8 AM daily until discharge or for 7 days, whichever came first.
  • Plasma arginine, kyotorphin, and NOx levels were measured, pK/pharmacodynamics analyses were performed, including determination of arginine maximum concentration (Cmax), time to reach Cmax (Tmax), area under the curve (AUC; calculated using the trapezoid rule), rate of clearance, and half-life.
  • Numeric pain scores were extracted from the electronic medical records. The daily highest/worst, lowest, and mean pain scores were assessed for correlations with the peak kyotorphin concentration, arginine Cmax, change in arginine concentration from baseline to discharge (pM), and peak NOx.
  • the mean plasma arginine peak for all participants was 331.6 ⁇ 95.4 pM, 30 minutes after infusion completion (Tmax). All participant except 1 achieved peak plasma arginine levels above the Km (100-150 pM) of the cationic amino acid transporter-1 after arginine infusion.
  • the AUC was the highest in the loading dose + continuous infusion arm. Kyotorphin levels were strongly correlated with plasma arginine concentration (Figure 2A).
  • Plasma NOx also significantly increased from pre-dose to Tmax, returning to baseline by 8 hours. Although NOx increased primarily in those receiving an argi nine-loading dose, no correlation was found between arginine and NOx concentration, arginine Cmax and peak NOx levels, or the mean change/percent change in NOx.
  • Arginine is contemplated to be the rate-limiting amino acid for kyotorphin production, potentially contributing to the efficacy of arginine therapy for pain reduction.
  • the opioid-sparing effect of arginine supplementation is not fully understood in SCD; induction of an endogenous opioid-like dipeptide, such as kyotorphin, represents a potential mechanism of analgesia that would decrease opioid utilization during VOE.
  • Arginine administered IV rapidly increased plasma arginine concentration 2 to 5 times above baseline at presentation for VOE, reaching a maximum concentration within 1 hour of infusion initiation, regardless of the study-dose administered.
  • the loading dose which was double the standard dose, interestingly, did not result in a significantly higher Cmax.
  • greater renal excretion or elevated metabolism of arginine are potential explanations, this observation may potentially reflect higher arginine intracellular transport in the loading dose arms, ultimately leading to changes in pharmacodynamic outcomes, such as mitochondrial function and oxidative stress, which favor the utilization of higher doses.
  • Arginine supplementation significantly increased plasma NOx levels, supporting the role of vasodilation as an additional potential mechanism of action during SCD-VOE.
  • Hemolysis depletes tetrahydrobiopterin (BH4), an essential cofactor for both tyrosine synthesis and NO production from arginine.
  • BH4 converts phenylalanine to tyrosine and is also a cofactor for NO synthase in the production of NO from arginine. Because BH4 is unstable, it becomes non enzymatically oxidized to dihydrobiopterin under oxidative stress, disrupting both metabolic pathways and compromising tyrosine synthesis and NO production.
  • BH4 is contemplated to disrupt both metabolic pathways compromising tyrosine synthesis and NO production, adversely impacting kyotorphin production, and potentially contributing to pain.
  • the addition use of BH4 is contemplated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention divulgue des compositions et des procédés de gestion de la douleur à l'aide de L-arginine. Dans certains modes de réalisation, la présente divulgation concerne des formulations pharmaceutiques comprenant de la L-arginine et une bioptérine telle que la tétrahydrobioptérine. Dans certains modes de réalisation, la composition pharmaceutique comprend en outre de l'acétaminophène et/ou de la N-acétylcystéine. Dans certains modes de réalisation, la formulation de L-arginine est un liquide aqueux approprié pour une injection intraveineuse qui augmente la formation endogène de kyotorphine.
PCT/US2024/042493 2023-08-15 2024-08-15 Formulations de l-arginine et procédés de gestion de la douleur Pending WO2025038846A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363519610P 2023-08-15 2023-08-15
US63/519,610 2023-08-15
US202363519938P 2023-08-16 2023-08-16
US63/519,938 2023-08-16

Publications (1)

Publication Number Publication Date
WO2025038846A1 true WO2025038846A1 (fr) 2025-02-20

Family

ID=94633121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/042493 Pending WO2025038846A1 (fr) 2023-08-15 2024-08-15 Formulations de l-arginine et procédés de gestion de la douleur

Country Status (1)

Country Link
WO (1) WO2025038846A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US20110281880A1 (en) * 2007-04-11 2011-11-17 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20190275047A1 (en) * 2009-07-22 2019-09-12 University Of Massachusetts Methods And Compositions To Reduce Oxidative Stress
US20200253976A1 (en) * 2017-09-28 2020-08-13 University Of Massachusetts Endothelial Facilitation in Neurodegerative Diseases by Cerebral Blood Flow Enhancement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281880A1 (en) * 2007-04-11 2011-11-17 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20190275047A1 (en) * 2009-07-22 2019-09-12 University Of Massachusetts Methods And Compositions To Reduce Oxidative Stress
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US20200253976A1 (en) * 2017-09-28 2020-08-13 University Of Massachusetts Endothelial Facilitation in Neurodegerative Diseases by Cerebral Blood Flow Enhancement

Similar Documents

Publication Publication Date Title
US10167467B2 (en) Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
JP6173437B2 (ja) スタチン及びω−３脂肪酸の組成物
ES2262741T3 (es) Uso de acidos grasos poliinsaturados para la prevencion de accidentes cardiovasculares importantes.
US20140275252A1 (en) Methods of treating traumatic brain injury
US20120178672A1 (en) Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
US20140221452A1 (en) Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
JP2016516040A5 (fr)
EP2217220B1 (fr) Composition de pastilles d'acide lipoïque
CN105120872A (zh) 包含15-ohepa的组合物以及其使用方法
US9968629B2 (en) Product and method for supporting uridine homeostasis
EP1390028A2 (fr) Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie
US11464753B2 (en) Composition for treatment of neurodegenerative disease
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
JP6401270B2 (ja) 徐放性固体経口組成物
WO2025038846A1 (fr) Formulations de l-arginine et procédés de gestion de la douleur
US20110117070A1 (en) Compositions and methods for treating headache
US20240307337A1 (en) Method Of Treatment Of Obesity
WO2017177160A1 (fr) Formulation destinée à être utilisée dans une méthode de traitement de la douleur
WO2023212326A1 (fr) Administration de r-bêta-hydroxybutyrate et de composés apparentés dans des applications vétérinaires
WO2012112527A1 (fr) Préparations à base d'oméga-3 comprenant epa, dha et dpa pour le traitement des facteurs de risque dans la maladie cardiovasculaire
WO2012112511A1 (fr) Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires
Adesanya et al. Nutrition in traumatic brain injury: focus on the immune modulating supplements
MX2011013989A (es) Combinacion farmaceutica.
WO1992022305A1 (fr) Composition therapeutique pour liberation prolongee de magnesium
JP2020503388A (ja) 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24854935

Country of ref document: EP

Kind code of ref document: A1